PLoS ONE 9 , e90633
La grande safena por ejemplo, es inocente
SechiGDeleddaMGBuaGSattaWMDeianaGAPesGMet al
The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication

It has also been proposed that sweet taste receptors (T1R2, T1R3) are involved in the glucose-sensing mechanism, but there is still some controversy about whether this is so (Reference Steinert, Gerspach and Gutmann29,Reference Kokrashvili, Mosinger and Margolskee30)
Professional guidance in designing these complex research protocols is highly recommended